Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiazhen Cui

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Experimental Hematology & Oncology|January 3, 2025
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemiaTingting Yang, Yetian Dong, Mingming Zhang, et al.
HLA|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical StudyHaiqiong Zheng, Houli Zhao, Xinyi Zhu, et al.
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 15, 2022
Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis PathwaysMi Shao, Xinyi Teng, Xin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.
Bone Marrow Transplantation|August 20, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphomaYetian Dong, Tingting Yang, Mengyu Zhao, et al.
Nature Aging|July 17, 2024
A metabolic atlas of blood cells in young and aged mice identifies uridine as a metabolite to rejuvenate aged hematopoietic stem cellsXiangjun Zeng, Ce Shi, Yingli Han, et al.
Cell Reports. Medicine|February 2, 2024
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolismYue Huang, Mi Shao, Xinyi Teng, et al.
The Lancet. Haematology|February 1, 2023
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialMingming Zhang, Guoqing Wei, Linghui Zhou, et al.
Journal of Hematology & Oncology|July 22, 2021
Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustionHao Zhang, Yongxian Hu, Mi Shao, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Experimental Hematology & Oncology|January 3, 2025
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemiaTingting Yang, Yetian Dong, Mingming Zhang, et al.
HLA|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical StudyHaiqiong Zheng, Houli Zhao, Xinyi Zhu, et al.
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 15, 2022
Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis PathwaysMi Shao, Xinyi Teng, Xin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.
Bone Marrow Transplantation|August 20, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphomaYetian Dong, Tingting Yang, Mengyu Zhao, et al.
Nature Aging|July 17, 2024
A metabolic atlas of blood cells in young and aged mice identifies uridine as a metabolite to rejuvenate aged hematopoietic stem cellsXiangjun Zeng, Ce Shi, Yingli Han, et al.
Cell Reports. Medicine|February 2, 2024
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolismYue Huang, Mi Shao, Xinyi Teng, et al.
The Lancet. Haematology|February 1, 2023
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialMingming Zhang, Guoqing Wei, Linghui Zhou, et al.
Journal of Hematology & Oncology|July 22, 2021
Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustionHao Zhang, Yongxian Hu, Mi Shao, et al.
Pageof 6